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Outside Start Cilostazol Bridge Study (Outpatient peri-Surgical Interruption
of Drug Eluting Stent Antiplatelet Regimen Testing A Cilostazol Bridge Study):
A 6 year experience
Charles L. Laham,1 Michael S. Chandra,2 Nicolas W. Shammas3
1Holy Family Memorial Hospital, Manitowoc, WI; 2Unitypoint Clinic Cardiology,
Cedar Rapids, IA; 3Midwest Cardiovascular Research Foundation, Davenport, IA
BACKGROUND Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor þ aspirin
(ASA) decreases drug-eluting stent (DES) thrombosis. Annually 5%-10% of DES pa-
tients (pts) are advised DAPT interruption to reduce peri-operative (peri-op) bleeding.
Premature DAPT stoppage especially early during the ﬁrst year after (post) 1st gen-
eration (F-Gen) DES leads to high stent thrombosis (ST) rates of 10-20%. Of all DES,
paclitaxel eluting DES have highest ST rates off DAPT with recent studies showing
associated major adverse cardiac event (MACE) rates persist for at least 30 months
post DES placement. There is no consensus as to the best bridging in DES patients
taken off DAPT preoperatively. The feasibility of outpatient cilostazol bridging of DES
off DAPT peri-op has not been formally tested. We report our 6 year experience with
cilostazol bridging during peri-op DAPT stoppage mostly in F-Gen paclitaxel DES
during periods of proven high ST/MACE risk.
METHODS From 2005 to 2010 we tested cilostazol bridging of DES in consecutive pts
advised to stop both DAPT peri-op. 2 dosing regimen intervals were tailored to reduce
risk and degree of expected peri-op bleeding. Initially DAPT was only advised for
6 months post DES and later extended to 1 year, thus early bridging was in urgent
unavoidable surgeries during the high risk ﬁrst 6-12 month post DES. When DAPT was
later advised long-term due to late ST reports, peri-op cilostazol bridging was
extended to all procedures up to 5 years post DES placement. MACE was felt related to
bridging if it occurred while off DAPT peri-op or within 30 days post-op. We hereby
report results for peri-op cilostazol bridging off DAPT from 2 weeks to 60 months post
latest DES.
DAPT was stopped after last doses on 8th day pre-op and cilostazol 100mg po bid
started on the 7th pre-op day: for low risk bleeding surgeries, cilostazol was stopped
24-30 hours (hrs) pre-op and DAPT resumption advised at 12-24 hrs post-op. For
moderate-high bleeding risk surgeries (epidurals; back & urology surgery, coronary
bypass) cilostazol was stopped 54-60 hrs pre-op after 1000 mg and DAPT resumed
24-36 hrs post-op. For those who didn’t tolerate cilostazol 100mg, dose was reduced
to 50mg po bid. Pts were deemed adequately bridged if they took at least 600 mg of
cilostazol pre-op and resumed DAPT within 48 hrs post-op.
RESULTS A total of 95 pts with DES’s underwent 167 consecutive surgeries advising
DAPT stoppage utilizing the cilostazol bridging and DAPT resumption protocols. 95%
of patients had 1 or more high ST risk paclitaxel DES. Pts were adequately bridged
during 157/167 surgeries with optimal dosing of 100mg bid (or 50mg if intolerant) and
DAPT resumed within 48 hrs. None of the 157 fully bridged experienced peri or post-
op MACE giving observed respective 100% compliant, and 94% intention to treat,
success rates for cilostazol DES bridging. In the remaining 10 patients that were
cilostazol intolerant, non-compliant and/or who failed DAPT resumption within
48 hrs post-op, 3 had MACE (Table) perioperatively or in the follow up period. Overall,
a very low MACE rate of 2% (ie. 1/48 bridged surgeries) was observed with cilostazol
off DAPT in the highest risk ﬁrst 12 months post DES when compared to historical
MACE rates of 10-20% with paclitaxel DES in the ﬁrst year post DES when DAPT
stopped prematurely without planned bridging. No signiﬁcant bleeding other than
nuisance bleeding occurred, none altering surgery success or requiring additional
transfusions over that typical of surgery type.
CONCLUSION Our study suggests that outpatient cilostazol peri-op bridging of DES
off DAPT is feasible and results in low bleeding and low MACE rates as seen in pa-
tients with ﬁrst generation DES when bridged off DAPT. Bridging success requires
strict adherence to the cilostazol regimen and DAPT resumption schedules. As new
generation DES have reported less ST risk & most surgeries don’t stop both DAPT, the
value of cilostazol bridging needs further conﬁrmation in current generation DES and
in those continuing ASA peri-op.
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Clinical Outcomes Of The BIOFLEX-I Study: Utilization Of Self Expanding Stents
In The Iliac Arteries
Mark W. Burket,1 Marianne Brodmann,2 Michael R. Jaff3
1University of Toledo Medical Center, Toledo, OH; 2Medical University of Graz, Graz,
Austria; 3Massachusetts General Hospital, Boston, MA
BACKGROUND Percutaneous transluminal angioplasty has historically been the
standard in minimally invasive treatment of peripheral artery disease (PAD). In iliac
arteries, self-expanding, nitinol stent technology has evolved as an effective treat-
ment of atherosclerotic lesions. BIOFLEX-I evaluates the safety and efﬁcacy of the
Astron stent in the iliac arteries.
METHODS The BIOFLEX-I study was a prospective, multicenter, non-randomized,
single arm, investigational device exemption (IDE) study performed in the United
States, Canada, and Europe. Thirty (30) study centers enrolled 161 evaluable study
subjects for treatment of de novo or restenotic lesions (140mm length) or occlusions
(100mm length) in common and/or external iliac arteries with reference vesseldiameters from 6 to 9mm. The primary endpoint was the composite rate of procedu
or stent related major adverse events (MAEs) at 12 months post index procedur
MAEs were deﬁned as 30-day mortality, clinically-indicated target lesion revasc
larization (TLR) and index limb amputation at 12 months. Results were compared to
pre-speciﬁed performance goal based on prior prospective, multicenter studies ut
lizing nitinol-based, self-expanding stents for the treatment of iliac lesions similar
those in this study. Core laboratories were utilized for independent conﬁrmation
angiography and duplex ultrasound ﬁndings. All site reported MAEs were adjudicate
by an independent Clinical Events Committee.
RESULTS For the BIOFLEX-I study of patients with iliac disease treated with th
Astron stent, the primary endpoint was met. The 12-month composite endpoint
MAE was 2.1% (3/146) (p<0.001) 95 % CI [0.4%, 5.9%]. The 30 day mortality rate w
0.7% (1/146) 95 % CI [0.0%, 3.8%]. Target lesion revascularization (TLR) rates at
months were 1.4% (2/146) 95 % CI [0.2%, 4.5%], and 12-month index limb amputatio
was 0.0% (0/146) 95 % CI [0.0%, 2.5%]. The secondary endpoint of primary patenc
was 89.8% (115/128) 95 % CI [83.3%, 94.5%] at 12 months.
CONCLUSION The 12-month outcomes of the BIOFLEX-I study for the Astron stent
iliac indications demonstrate a low MAE rate, high primary patency, and a low rate
TLR. This supports the safety and efﬁcacy of the self-expanding, nitinol stent f
treatment of atherosclerotic lesions in the iliac arteries.
CRT-321
Passeo-18 Lux Drug Releasing Balloon: 12-month Update From The Biolux P-I An
Biolux P-II Studies And The Biolux P-III All-comers Study Design
Marianne Brodmann,1 Thomas Zeller,2 Dierk Scheinert,3 Karl-Ludwig Schulte,4
Marc Bosiers,5 Patrick Peeters,6 Johannes Lammer,7 Ernst Pilger,1 Gunnar Tepe8
1Medical University of Graz, Graz, Austria; 2Universitäts-Herzzentrum Freiburg Bad
Krozingen, Bad Krozingen, Germany; 3Universitätsklinikum Leipzig, Leipzig, German
4Ev. Krankenhaus Koenigen Elizabeth Herzberge, Berlin, Germany; 5AZ Sint Blasius
Dendermonde, Belgium; 6Imelda Ziekenhuis, Bonheiden, Belgium;
7Universitätsklinikum für Radiodiagnostik, AKH Wien, Vienna, Austria; 8RoMed
Klinikum Rosenheim, Rosenheim, Germany
PURPOSE Drug releasing balloon (DRB) angioplasty has evolved to a paradigm-shi
in the endovascular treatment of peripheral artery disease (PAD). The current ev
dence base has been fuelled mostly by clinical trials with restrictive eligibility criteri
excluding most patients treated in daily practice.
METHODS BIOLUX P-I and BIOLUX P-II were prospective, international, multicentr
ﬁrst-in-human, randomized controlled trials investigating the safety and efﬁcacy
the Passeo-18 Lux DRB in the femoropopliteal and infrapopliteal arteries, respe
tively. BIOLUX P-III is a global, prospective, international, multicentre, all-come
study to enroll at least 700 patients with infrainguinal artery lesions treated with th
Passeo-18 Lux DRB. The clinical and performance primary endpoints are maj
adverse events at 6 months and freedom from clinically-driven target lesion reva
cularization at 12 months, respectively. Pre-speciﬁed analysis subgroups includ
Age65; Diabetes; Renal Insufﬁciency; Rutherford Category3; Popliteal, Infr
popliteal, TASC C&D and heavily calciﬁed lesions.
RESULTS BIOLUX P-III will build and expand on safety and performance outcom
from the BIOLUX P-I and BIOLUX P-II studies: BIOLUX P-I demonstrated signiﬁca
differences in late lumen loss, TLR and binary restenosis in favour of th
Passeo-18 Lux compared to control PTA in femoropopliteal lesions. In BIOLUX P-
Rutherford Class 5 patients with infrapopliteal lesions demonstrated signiﬁca
clinical improvement at 6 months. Updated 12 month results from both studies will b
presented.
CONCLUSION With inclusion and exclusion criteria that reﬂect complex, ‘real-worl
clinical practice, BIOLUX P-III will further illuminate the role of DRB, alone or
combination with other treatment modalities, in the contemporary management
patients with infrainguinal PAD (ClinicalTrials.gov Identiﬁer: NCT02276313).
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Long Term Clinical Data Of The BIOSOLVE-I Study With The Paclitaxel-eluting
Absorbable Magnesium Scaffold (DREAMS) And Multi-modality Imaging Analys
Michael Haude,1 Raimund Erbel,2 Paul Erne,3 Stefan Verheye,4 Paul Vermeersch,4
Hubertus Degen,1 Dirk Böse,2 Ron Waksman,5 Neil J. Weissmann,5 Francesco Prati,6
Jacques Koolen7
1Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany; 2West Germa
Heart Center, Essen, Germany; 3Kantonspital Luzern, Luzern, Switzerland; 4ZNA
Middelheim, Antwerp, Belgium; 5MedStar Health Research Institute, Washington, D
6Rome Heart Research, Rome, Italy; 7Catharina Ziekenhuis, Eindhoven, Netherlands
OBJECTIVES In order to assess the long term safety, clinical performance and th
bioabsorption process of the paclitaxel-eluting absorbable magnesium Scaffo
(DREAMS) 3-year clinical data and multi-modality imaging outcomes are reported.
METHOD Forty-six subjects were enrolled in the ﬁrst-in-man BIOSOLVE-I study
two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months; angi
graphic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12-month.
subgroup of patients underwent OCT and vasomotion testing. The primary endpoi
